Anti-thymocyte globulin (ATG)

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Advancing Transplantation Outcomes in Children

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

Diabetes Islet Preservation Immune Treatment

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

ATG-GCSF in New Onset Type 1 Diabetes

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Cord Blood Transplantation for Patients With Cancer

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Infusion of Expanded Cord Blood T Cells

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients